ES2539861T3 - Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos - Google Patents
Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos Download PDFInfo
- Publication number
- ES2539861T3 ES2539861T3 ES11833207.1T ES11833207T ES2539861T3 ES 2539861 T3 ES2539861 T3 ES 2539861T3 ES 11833207 T ES11833207 T ES 11833207T ES 2539861 T3 ES2539861 T3 ES 2539861T3
- Authority
- ES
- Spain
- Prior art keywords
- clevidipin
- antimicrobial agents
- formulations containing
- amount
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una formulación farmacéutica que comprende (a) clevidipina, o una sal o un éster farmacéuticamente aceptables de la misma, presente en una cantidad de aproximadamente el 0,01 hasta aproximadamente el 1,0 % p/v, (b) un agente antimicrobiano, presente en una cantidad de aproximadamente el 0,001 hasta aproximadamente el 1,0 % p/v, (c) un lípido, presente en una cantidad de aproximadamente el 2 hasta aproximadamente el 30 % p/v, (d) un emulsionante, presente en una cantidad de aproximadamente el 0,2 hasta aproximadamente el 2,0 % p/v, (e) un modificador de la tonicidad, presente en una cantidad de aproximadamente el 2 hasta aproximadamente el 3 % p/v, y (f) agua hasta el 100 %; en la que el agente antimicrobiano es EDTA.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39229410P | 2010-10-12 | 2010-10-12 | |
US392294P | 2010-10-12 | ||
PCT/US2011/055617 WO2012051116A1 (en) | 2010-10-12 | 2011-10-10 | Clevidipine emulsion formulations containing antimicrobial agents |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2539861T3 true ES2539861T3 (es) | 2015-07-06 |
ES2539861T5 ES2539861T5 (es) | 2018-11-16 |
Family
ID=45925617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11833207.1T Active ES2539861T5 (es) | 2010-10-12 | 2011-10-10 | Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos |
Country Status (18)
Country | Link |
---|---|
US (1) | US10010537B2 (es) |
EP (1) | EP2627173B2 (es) |
JP (3) | JP6040437B2 (es) |
KR (2) | KR20130101080A (es) |
CN (1) | CN103237446B (es) |
AU (1) | AU2011313852B2 (es) |
BR (1) | BR112013008601B1 (es) |
CA (1) | CA2814495C (es) |
DK (1) | DK2627173T4 (es) |
EA (1) | EA022849B1 (es) |
ES (1) | ES2539861T5 (es) |
HK (1) | HK1187495A1 (es) |
HU (1) | HUE026295T2 (es) |
MX (2) | MX2013004151A (es) |
NZ (1) | NZ610465A (es) |
PL (1) | PL2627173T5 (es) |
PT (1) | PT2627173E (es) |
WO (1) | WO2012051116A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5674660B2 (ja) | 2008-08-01 | 2015-02-25 | ザ メディシンズ カンパニー | 医薬組成物および不純物の濃度が低い医薬組成物の製造方法 |
US8658676B2 (en) | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
WO2012051116A1 (en) | 2010-10-12 | 2012-04-19 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
JP2014509654A (ja) * | 2011-04-01 | 2014-04-21 | ザ メディシンズ カンパニー | 脳卒中損傷の低減に使用するための短時間作用型ジヒドロピリジン(クレビジピン) |
BR112015009291B1 (pt) * | 2012-10-26 | 2021-03-16 | Chiesi Farmaceutici S.P.A | uso de clevidipina para controle da pressão arterial e redução da dispneia na insuficiência cardíaca |
CN103169672A (zh) * | 2012-12-26 | 2013-06-26 | 辰欣药业股份有限公司 | 一种丁酸氯维地平冻干乳剂 |
CN103110580B (zh) * | 2013-02-20 | 2014-09-17 | 北京德立福瑞医药科技有限公司 | 丁酸氯维地平注射剂 |
CN103126986A (zh) * | 2013-03-19 | 2013-06-05 | 董慧芳 | 一种丁酸氯维地平静脉注射用乳剂及其制备方法 |
TW201538181A (zh) * | 2014-03-19 | 2015-10-16 | Pures Biotech Co Ltd | 用於潤滑保濕消毒滅菌之半流體組成物及其使用方法 |
US11737989B2 (en) * | 2014-05-19 | 2023-08-29 | Chiesi Farmaceutici S.P.A. | Clevidipine nanoparticles and pharmaceutical compositions thereof |
CN105456189A (zh) * | 2014-09-12 | 2016-04-06 | 武汉大安制药有限公司 | 一种丁酸氯维地平乳剂注射剂及其制备方法 |
CN104523590B (zh) * | 2014-12-09 | 2017-09-15 | 山东威高药业股份有限公司 | 一种丁酸氯维地平脂肪乳注射液 |
CN107661294B (zh) * | 2016-07-27 | 2020-04-14 | 武汉科福新药有限责任公司 | 抗高血压药物脂肪乳注射剂及其制备方法 |
US20200316043A1 (en) * | 2017-12-20 | 2020-10-08 | Aurobindo Pharma Ltd. | Pharmaceutical composition comprising clevidipine and process for preparation thereof |
CN108324703B (zh) * | 2018-01-26 | 2020-07-28 | 中国医学科学院阜外医院 | 用于保护缺血心肌的注射剂及其制备方法 |
CN109602704A (zh) * | 2019-01-23 | 2019-04-12 | 广东嘉博制药有限公司 | 丁酸氯维地平脂肪乳注射液及其制备工艺 |
CN109776405A (zh) * | 2019-03-07 | 2019-05-21 | 重庆安格龙翔医药科技有限公司 | 一种丁酸氯维地平杂质的制备方法 |
US11135208B2 (en) | 2019-08-12 | 2021-10-05 | American Regent, Inc. | 1,4-dihydropyridine compositions, methods of making and use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4217842A1 (de) | 1992-05-29 | 1993-12-02 | Dietl Hans | Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung |
JPH08506081A (ja) | 1993-02-12 | 1996-07-02 | ファーモス コーポレイション | サブミクロン・エマルジョンの調製のための乾燥組成物 |
SE9303657D0 (sv) | 1993-11-05 | 1993-11-05 | Astra Ab | Short-acting dihydropyridines |
SE9303744D0 (sv) | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
GB9405593D0 (en) | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
IT1275532B (it) | 1995-07-14 | 1997-08-07 | Recordati Chem Pharm | Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa |
CA2262578A1 (en) | 1996-08-07 | 1998-02-12 | Kunio Ito | Fat emulsion containing xanthine derivative |
NZ505948A (en) | 1998-02-10 | 2003-10-31 | Sicor Inc | Propofol composition containing sulfite as a preservative to prevent bacterial growth of Staphylococcus, Escherichia, Pseudomonas and Candida |
IT1301807B1 (it) | 1998-06-25 | 2000-07-07 | Tiberio Bruzzese | Formulazioni farmaceutiche iniettabili di derivati della partricina. |
ATE285795T1 (de) | 1998-07-14 | 2005-01-15 | Alcon Mfg Ltd | Polypropylenbasierte behälter für prostaglandin- enthaltende produkte |
SE9804002D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New manufacturing process |
GB0012597D0 (en) | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
NZ538255A (en) * | 2002-07-29 | 2006-11-30 | Transform Pharmaceuticals Inc | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
US20050186230A1 (en) * | 2004-01-23 | 2005-08-25 | Sd Pharmaceuticals, Inc. | Elemene compositions containing liquid oil |
DK1720893T3 (en) | 2004-02-26 | 2014-11-24 | Baylor Res Inst | COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS |
US20050271710A1 (en) | 2004-06-04 | 2005-12-08 | Argo Brian P | Antimicrobial tissue products with reduced skin irritation potential |
US20050282895A1 (en) | 2004-06-21 | 2005-12-22 | Dosch Michael H | Antimicrobial compositions and methods of use thereof |
CA2626357A1 (en) * | 2005-10-20 | 2007-04-26 | Nastech Pharmaceutical Company Inc. | Intranasal administration of rapid acting insulin |
FR2900052B1 (fr) | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
WO2008013785A2 (en) | 2006-07-24 | 2008-01-31 | Singh-Broemer And Company, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
AU2007332800A1 (en) | 2006-12-07 | 2008-06-19 | Avicena Group, Inc. | Creatine compositions for skin treatment |
CN101873858B (zh) | 2007-06-11 | 2016-05-25 | R·骆克·麦克唐纳 | 用于预防脑血管痉挛的药物递送*** |
EP2008651A1 (en) | 2007-06-26 | 2008-12-31 | Drug Delivery Solutions Limited | A bioerodible patch |
JP5674660B2 (ja) | 2008-08-01 | 2015-02-25 | ザ メディシンズ カンパニー | 医薬組成物および不純物の濃度が低い医薬組成物の製造方法 |
KR20160095206A (ko) | 2008-08-01 | 2016-08-10 | 더 메디슨스 컴퍼니 | 약제학적 조성물 및 이를 안정화시키는 방법 |
CA2734780C (en) * | 2008-08-22 | 2016-07-05 | Milestone Pharmaceuticals Inc. | Short acting benzothiazepine calcium channel blockers and uses thereof |
US20100130619A1 (en) | 2008-11-24 | 2010-05-27 | Joseph Schwarz | Pharmaceutical composition for parenteral administration of idebenone |
CN101766668B (zh) | 2008-12-30 | 2011-11-23 | 上海中医药大学 | 牛蒡子提取物及其制备方法和用途 |
CN101766568A (zh) | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | 一种含有氯维地平的乳剂及其制备工艺和用途 |
DE102009003980A1 (de) | 2009-01-07 | 2010-07-08 | B. Braun Melsungen Ag | Propofol in triheptanoinhaltiger Trägeremulsion |
CN101791311A (zh) | 2009-12-31 | 2010-08-04 | 广州中大创新药物研究与开发中心有限公司 | 一种具有短效降压作用的药物组合物 |
CN101780036B (zh) | 2010-03-30 | 2011-11-16 | 武汉武药科技有限公司 | 丁酸氯维地平脂微球注射液及其制备方法 |
WO2012051116A1 (en) | 2010-10-12 | 2012-04-19 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
-
2011
- 2011-10-10 WO PCT/US2011/055617 patent/WO2012051116A1/en active Application Filing
- 2011-10-10 KR KR1020137012057A patent/KR20130101080A/ko active Application Filing
- 2011-10-10 DK DK11833207.1T patent/DK2627173T4/en active
- 2011-10-10 ES ES11833207.1T patent/ES2539861T5/es active Active
- 2011-10-10 MX MX2013004151A patent/MX2013004151A/es active IP Right Grant
- 2011-10-10 NZ NZ610465A patent/NZ610465A/en unknown
- 2011-10-10 JP JP2013533916A patent/JP6040437B2/ja active Active
- 2011-10-10 CA CA2814495A patent/CA2814495C/en active Active
- 2011-10-10 EA EA201390541A patent/EA022849B1/ru unknown
- 2011-10-10 MX MX2014014773A patent/MX356537B/es unknown
- 2011-10-10 PL PL11833207T patent/PL2627173T5/pl unknown
- 2011-10-10 PT PT118332071T patent/PT2627173E/pt unknown
- 2011-10-10 KR KR1020167006219A patent/KR101786857B1/ko active IP Right Grant
- 2011-10-10 HU HUE11833207A patent/HUE026295T2/en unknown
- 2011-10-10 BR BR112013008601-7A patent/BR112013008601B1/pt active IP Right Grant
- 2011-10-10 EP EP11833207.1A patent/EP2627173B2/en active Active
- 2011-10-10 US US13/270,004 patent/US10010537B2/en active Active
- 2011-10-10 CN CN201180048865.XA patent/CN103237446B/zh not_active Ceased
- 2011-10-10 AU AU2011313852A patent/AU2011313852B2/en active Active
-
2014
- 2014-01-22 HK HK14100653.2A patent/HK1187495A1/xx unknown
- 2014-06-11 JP JP2014120354A patent/JP6437743B2/ja active Active
-
2016
- 2016-06-22 JP JP2016123498A patent/JP6326094B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2539861T3 (es) | Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
ES2606342T3 (es) | Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos | |
ES2494442T3 (es) | Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
ES2531646T3 (es) | Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno | |
ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
CL2019000209A1 (es) | Formulación novedosa administrable por la vía oral. | |
ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
CL2017000829A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. | |
BR112014031837A2 (pt) | formulações de progesterona | |
JP2015520235A5 (es) | ||
ES2532948T3 (es) | Composición tópica para el tratamiento de queratosis actínica | |
CL2011001225A1 (es) | Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. | |
AR074391A1 (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
PE20090910A1 (es) | Composicion topica | |
ES2624577T3 (es) | Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea | |
CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
CL2012003654A1 (es) | Formulación farmaceutica estable para administracion intratecal que comprende una proteina arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromática (mld). | |
ES2478264T3 (es) | Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica | |
CL2011001621A1 (es) | Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos. | |
ECSP066670A (es) | Prodroga florfenicol con mejor solubilidad en agua | |
PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol |